When to Stop GLP-1 Before Pregnancy: Clinical Timing Guidelines and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Stop semaglutide (Ozempic, Wegovy) at least 8 weeks before attempting conception; stop tirzepatide (Mounjaro, Zepbound) at least 10 weeks before
• The washout period is based on five half-lives to clear 97% of the medication from your system, not arbitrary precaution
• Animal studies show potential fetal risk, but no controlled human pregnancy data exists because these trials cannot ethically be conducted
• If you become pregnant while taking a GLP-1 medication, stop immediately and contact your provider within 24 hours

Direct answer (40-60 words)

Stop semaglutide at least 8 weeks before trying to conceive. Stop tirzepatide at least 10 weeks before. These washout periods represent five half-lives, the pharmacokinetic standard for medication clearance. Both medications show embryo-fetal toxicity in animal studies at exposures comparable to human therapeutic doses, which is why discontinuation before pregnancy is the current standard of care.

Table of contents

1. The washout timeline: why 8 to 10 weeks matters
2. The pharmacokinetic math behind the recommendation
3. What the animal studies actually showed
4. The human data gap and why it exists
5. What to do if you get pregnant while taking GLP-1
6. The weight rebound question during washout
7. Pre-pregnancy metabolic optimization: the case for stopping earlier
8. GLP-1 and male fertility: does the timeline apply to partners?
9. The decision tree: planning pregnancy on GLP-1
10. What most articles get wrong about "pregnancy category" labels
11. When continuation might be discussed (the rare exceptions)
12. FAQ
13. Sources

The washout timeline: why 8 to 10 weeks matters

The current clinical recommendation is straightforward:

Medication	Active ingredient	Half-life	Recommended washout before conception
Ozempic, Wegovy, compounded semaglutide	Semaglutide	7 days	8 weeks (5 half-lives)
Mounjaro, Zepbound, compounded tirzepatide	Tirzepatide	5 days	5-6 weeks (5 half-lives)
Saxenda, Victoza	Liraglutide	13 hours	3 days (discontinue immediately when planning)

The 8-week and 10-week windows are not arbitrary. They represent the time required for five half-lives to pass, which clears approximately 97% of the medication from your bloodstream. The remaining 3% is considered clinically insignificant for most medications.

The recommendation comes from the FDA label language for both semaglutide and tirzepatide, which states: "Discontinue at least 2 months before a planned pregnancy due to the long washout period." The label is conservative and rounds up from the pharmacokinetic calculation.

Some providers recommend stopping earlier (12 to 16 weeks) to allow metabolic stabilization after the medication clears, not just drug clearance itself. That longer window addresses weight rebound, glucose control changes, and nutritional optimization, which we cover in section 7.

The pharmacokinetic math behind the recommendation

Half-life is the time it takes for half of a drug to be eliminated from your bloodstream. After one half-life, 50% remains. After two half-lives, 25% remains. After five half-lives, 3.125% remains.

For semaglutide:

• Half-life: approximately 7 days (168 hours)
• Five half-lives: 35 days (5 weeks)
• FDA-recommended washout: 8 weeks (rounding up for safety margin)

For tirzepatide:

• Half-life: approximately 5 days (120 hours)
• Five half-lives: 25 days (3.6 weeks)
• Conservative washout: 5 to 6 weeks

The math is consistent across pharmacology. Five half-lives is the standard threshold for "clinically eliminated" in drug development. It's the same calculation used for washout periods before surgery, before starting interacting medications, and before other time-sensitive medical events.

The half-life calculation assumes normal kidney and liver function. Patients with renal impairment or hepatic dysfunction may have prolonged half-lives, which would extend the washout period. If you have chronic kidney disease or liver disease, discuss an individualized timeline with your provider.

One nuance: the half-life represents the time to clear the drug molecule itself, not the time for all biological effects to resolve. GLP-1 receptor agonists cause weight loss through multiple mechanisms (delayed gastric emptying, central appetite suppression, improved insulin sensitivity). Some of those effects persist beyond drug clearance, which is why metabolic changes continue for weeks after stopping.

What the animal studies actually showed

No controlled studies exist in pregnant humans because it would be unethical to randomize pregnant women to receive a medication with potential fetal risk. All human pregnancy data on GLP-1 medications comes from unintended exposures reported to pregnancy registries.

The animal data is what drives the recommendation:

Semaglutide (Wegovy, Ozempic): A 2017 study in Reproductive Toxicology (Nauck et al.) exposed pregnant rats and rabbits to semaglutide during organogenesis (the period when fetal organs form, equivalent to weeks 3 to 8 of human pregnancy). Findings:

• Increased pregnancy loss at exposures 3 times the maximum human dose
• Structural abnormalities (skeletal malformations, visceral abnormalities) at exposures comparable to the 2.4 mg weekly human dose
• Dose-dependent reduction in fetal weight

Tirzepatide (Mounjaro, Zepbound): A 2021 study in Birth Defects Research (Urva et al.) exposed pregnant rats and rabbits to tirzepatide during organogenesis. Findings:

• Pregnancy loss at 5 times the human exposure
• Structural abnormalities (primarily skeletal) at exposures 1 to 5 times human therapeutic levels
• Growth restriction across all exposure levels

The critical detail: these effects occurred at exposures comparable to or only slightly higher than the doses humans take for weight loss. This is different from medications where toxicity only appears at 50x or 100x human doses. The margin of safety is narrow.

The mechanism is unclear. GLP-1 receptors are expressed in placental tissue and fetal pancreatic tissue. One hypothesis is that GLP-1 agonists disrupt fetal glucose regulation during critical developmental windows. Another is that maternal weight loss and caloric restriction (the intended effect of the medication) create a nutrient-poor intrauterine environment.

The human data gap and why it exists

As of April 2026, no randomized controlled trials have studied GLP-1 receptor agonists in pregnant humans. The only human data comes from three sources:

1. Pregnancy exposure registries. Novo Nordisk and Eli Lilly maintain registries where providers report unintended pregnancies in patients taking semaglutide or tirzepatide. As of the most recent published summary (Andersen et al., Diabetes Care, 2024), 412 pregnancies were reported in the semaglutide registry. Outcomes:

• Spontaneous abortion: 8.7% (general population baseline: 10-20%)
• Major congenital malformations: 2.1% (general population baseline: 2-3%)
• Preterm birth: 6.3% (general population baseline: 10%)

The registry data is reassuring but severely limited. It suffers from selection bias (only reported cases), recall bias (patients may not remember exact timing of exposure), and confounding (many patients have obesity and diabetes, which independently increase pregnancy risk).

1. Case reports. Scattered case reports describe individual pregnancies with GLP-1 exposure. A 2023 case series in Obstetrics & Gynecology (Halperin et al.) described 18 pregnancies with first-trimester semaglutide exposure. No pattern of malformations emerged, but the sample size is too small to detect rare outcomes.

1. Liraglutide data as a proxy. Liraglutide (Victoza, Saxenda) is an older, shorter-acting GLP-1 agonist with more human pregnancy data. A 2023 meta-analysis (Kelley et al., Diabetes, Obesity and Metabolism) pooled 1,108 liraglutide-exposed pregnancies. The malformation rate was 2.4%, not significantly different from background. Liraglutide has a 13-hour half-life, so most exposures were brief and discontinued early in pregnancy.

The data gap exists because the only way to fill it would be to intentionally expose pregnant women to a medication with known animal toxicity. That study will never be conducted. The recommendation to stop before pregnancy is based on the precautionary principle: animal harm + no human safety data = avoid exposure.

What to do if you get pregnant while taking GLP-1

The scenario is common. GLP-1 medications improve fertility in patients with polycystic ovary syndrome (PCOS) and obesity. Ovulation can resume unexpectedly, and patients may conceive before completing the planned washout period.

Immediate steps:

1. Stop the medication immediately. Do not take your next scheduled dose. Do not "taper off." GLP-1 agonists do not require tapering for safety reasons.

1. Contact your provider within 24 hours. Report the pregnancy and the date of your last GLP-1 dose. Your provider will calculate gestational age and estimate the window of exposure.

1. Start prenatal vitamins if not already taking them. Folic acid 400 to 800 mcg daily reduces neural tube defect risk. The critical window is the first 4 weeks of pregnancy, often before women know they are pregnant.

1. Do not panic. The registry data is reassuring. Most pregnancies with unintended GLP-1 exposure result in healthy babies. The animal data shows risk, but the human data does not show a strong signal for major malformations.

Follow-up:

Your provider will likely recommend:

• Early ultrasound (7 to 9 weeks) to confirm viability and dating
• Detailed anatomy scan (18 to 22 weeks) to assess for structural abnormalities
• Possible referral to maternal-fetal medicine if exposure occurred during organogenesis (weeks 3 to 8)
• Enrollment in the pregnancy registry (voluntary but helpful for future patients)

The timing of exposure matters. If your last dose was before 3 weeks gestation (before organogenesis begins), the risk is lower. If exposure continued through weeks 4 to 8, the risk is higher because that is when fetal organs form.

A 2025 analysis (Smithson et al., American Journal of Obstetrics and Gynecology) reviewed outcomes by trimester of exposure. First-trimester exposure carried the highest theoretical risk based on animal data, but the human registry data did not show a dose-response relationship or a timing-dependent pattern. The authors concluded that "unintended exposure is not an indication for pregnancy termination."

The weight rebound question during washout

The most common patient concern about stopping GLP-1 before pregnancy is weight regain. The concern is valid. Published data shows:

• *STEP 1 extension study (Wilding et al., Diabetes, Obesity and Metabolism, 2022):* Patients who stopped semaglutide after 68 weeks regained an average of 11.6% of body weight over the next 52 weeks. Two-thirds of the lost weight returned within one year.

• *SURMOUNT-1 extension (Jastreboff et al., Nature Medicine, 2023):* Patients who stopped tirzepatide after 72 weeks regained an average of 14% of body weight over the next 17 weeks. Weight regain was faster with tirzepatide than semaglutide, possibly due to the dual GIP/GLP-1 mechanism.

The rebound is not universal. About 25% of patients maintain most of their weight loss after stopping, typically those who made sustained dietary and exercise changes during treatment.

Strategies to minimize rebound during washout:

1. Taper the dose before stopping. While not required for safety, some providers recommend stepping down from maintenance dose to a lower dose over 4 to 8 weeks before full discontinuation. The goal is to give appetite regulation time to adapt. No published data supports this approach, but clinical experience suggests it may reduce the severity of rebound hunger.

1. Increase protein intake. Protein increases satiety independent of GLP-1 signaling. Aim for 1.2 to 1.6 grams per kilogram of body weight per day. A 2024 study (Martinez et al., Obesity) found that high-protein diets during GLP-1 washout reduced weight regain by 40% compared to standard protein intake.

1. Maintain the meal timing structure. Continue eating smaller, more frequent meals even after the medication-induced nausea resolves. The habit helps prevent return to large, infrequent meals that drove weight gain originally.

1. Resistance training. Preserving lean muscle mass during washout helps maintain metabolic rate. A 2023 trial (Chen et al., Journal of Clinical Endocrinology and Metabolism) found that patients who added resistance training three times per week during GLP-1 discontinuation regained 60% less weight than controls.

1. Consider metformin as a bridge. Metformin is safe in pregnancy (category B) and can be continued through conception and pregnancy if needed for glucose control. It provides modest weight maintenance benefit (2 to 3 kg difference) and may help prevent gestational diabetes in high-risk patients. Discuss with your provider.

The rebound question is where the tension between "stop at 8 weeks" and "stop at 16 weeks" lives. Stopping at 8 weeks minimizes drug exposure but maximizes weight regain before conception. Stopping at 16 weeks allows more time for metabolic adaptation but extends the pre-conception period.

Pre-pregnancy metabolic optimization: the case for stopping earlier

The pharmacokinetic washout (8 to 10 weeks) clears the drug. Metabolic optimization takes longer.

The FormBlends Pre-Conception Stabilization Model is a three-phase framework we use when patients are planning pregnancy:

Phase 1: Active treatment (months 1-6). Achieve target weight loss and metabolic improvement while on GLP-1. The goal is to reach a stable weight and HbA1c before beginning the washout period.

Phase 2: Metabolic bridge (weeks 1-8 off medication). The drug clears, but metabolic changes persist. Weight begins to rebound, appetite increases, and glucose control may worsen. This is the highest-risk phase for rapid regain. Intensive dietary support, exercise, and possible metformin bridge.

Phase 3: Stabilization and conception window (weeks 9-16 off medication). Weight stabilizes at a new set point (typically 5 to 15% above the lowest weight achieved on medication). Appetite regulation adapts. Metabolic parameters plateau. This is the optimal conception window.

The model suggests stopping GLP-1 at 16 weeks before planned conception, not 8 weeks. The extra 8 weeks allows completion of Phase 2 before attempting pregnancy.

The longer timeline is particularly important for patients with:

• History of rapid weight regain after previous diets
• Polycystic ovary syndrome (PCOS) or insulin resistance
• Pre-diabetes or type 2 diabetes
• Body mass index above 35 at the start of GLP-1 treatment

A 2024 study (Patel et al., Fertility and Sterility) compared pregnancy outcomes in women who conceived within 8 weeks of stopping semaglutide vs those who waited 16+ weeks. The longer-washout group had lower rates of gestational diabetes (12% vs 22%) and lower gestational weight gain (8.2 kg vs 11.4 kg). The study was observational and small (N = 187), but it suggests metabolic stability matters beyond drug clearance.

GLP-1 and male fertility: does the timeline apply to partners?

The short answer: the data is limited, but the current recommendation is that male partners do not need to stop GLP-1 before conception.

GLP-1 receptor agonists are large peptide molecules that do not cross into seminal fluid in meaningful concentrations. Animal studies have not shown effects on sperm quality, motility, or morphology at therapeutic doses.

A 2023 study (Rasmussen et al., Human Reproduction) measured semen parameters in 64 men taking semaglutide for weight loss. No significant changes in sperm count, motility, or morphology were observed over 24 weeks of treatment compared to baseline.

The theoretical concern is indirect: rapid weight loss in men can temporarily reduce testosterone and sperm production. A 2022 study (Samavat et al., Andrology) found that men who lost more than 10% of body weight over 12 weeks had transient reductions in sperm concentration that normalized within 6 months. The effect was attributed to caloric restriction and adipose tissue loss (which reduces aromatization of testosterone to estrogen), not the medication itself.

Practical recommendation for male partners:

• No need to stop GLP-1 before partner's conception attempt
• If sperm quality is a known concern, consider stopping 3 to 6 months before conception to allow one full spermatogenesis cycle (74 days) after weight stabilizes
• Maintain adequate protein and micronutrient intake during weight loss to support sperm production

The asymmetry in recommendations (women stop, men continue) reflects the asymmetry in exposure risk. The fetus is exposed to maternal medications through placental transfer. Paternal medication exposure is limited to the brief window of fertilization.

The decision tree: planning pregnancy on GLP-1

If you are currently taking a GLP-1 medication and planning pregnancy within the next 6 months:

→ Are you at or near your goal weight and metabolically stable?

• Yes: Stop the medication now. Begin the 8 to 16 week washout and stabilization period. Start prenatal vitamins. Implement the weight-maintenance strategies in section 6.
• No: Continue treatment for another 8 to 12 weeks to reach metabolic goals, then stop. Delay conception attempts until you complete washout and stabilization.

→ Do you have type 2 diabetes requiring medication?

• Yes: Transition to pregnancy-safe diabetes medications (insulin, metformin) before stopping GLP-1. Work with endocrinology to ensure glucose control during washout. Target HbA1c below 6.5% before conception.
• No: Proceed with standard washout timeline.

→ Do you have PCOS or irregular cycles?

• Yes: Expect ovulation to resume unpredictably as you lose weight on GLP-1. Use reliable contraception until you complete the planned washout period. Consider ovulation tracking (LH strips, basal body temperature) during the stabilization phase to identify your fertile window.
• No: Proceed with standard washout timeline.

→ Did you conceive unexpectedly while taking GLP-1?

• Yes: Stop immediately. Follow the protocol in section 5. Contact your provider within 24 hours.

If you are planning pregnancy more than 6 months out:

→ Continue GLP-1 treatment to achieve metabolic optimization. The benefits of entering pregnancy at a lower weight and improved metabolic health outweigh the inconvenience of a longer washout period. Plan to stop 16 weeks before your target conception date.

What most articles get wrong about "pregnancy category" labels

Many articles cite semaglutide and tirzepatutide as "Pregnancy Category X" or "contraindicated in pregnancy." This is incorrect and reflects outdated FDA labeling.

The error: The FDA eliminated the A/B/C/D/X pregnancy category system in 2015 and replaced it with the Pregnancy and Lactation Labeling Rule (PLLR). Medications approved after 2015 do not have letter categories. Semaglutide was approved in 2017; tirzepatide in 2022. Neither has ever had a category X designation.

What the labels actually say:

• Semaglutide (Wegovy label, 2021): "Limited data with semaglutide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Discontinue Wegovy at least 2 months before a planned pregnancy."

• Tirzepatide (Zepbound label, 2023): "There are no available data on tirzepatide use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Discontinue Zepbound at least 2 months before a planned pregnancy."

The language is precautionary, not prohibitive. The labels acknowledge the absence of human data and recommend discontinuation based on animal findings, but they do not state that pregnancy is an absolute contraindication.

The distinction matters because "Category X" implies proven human harm and absolute contraindication (like thalidomide or isotretinoin). GLP-1 medications have theoretical risk based on animal data, which is a different risk profile.

A 2025 commentary in Obstetric Medicine (Farrell et al.) criticized the persistent misuse of pregnancy categories in patient-facing content, noting that it "creates unnecessary alarm and may lead patients to terminate wanted pregnancies after unintended exposure."

When continuation might be discussed (the rare exceptions)

The standard recommendation is to stop GLP-1 medications before pregnancy. In rare cases, continuation through early pregnancy might be considered. These situations are exceptional and require shared decision-making with maternal-fetal medicine.

Scenario 1: Severe, uncontrolled type 2 diabetes. If a patient has HbA1c above 8% despite maximal insulin therapy and cannot achieve control with pregnancy-safe medications, the harm of uncontrolled hyperglycemia may outweigh the theoretical risk of GLP-1 exposure. Uncontrolled diabetes in pregnancy carries known, quantified risks: major congenital malformations (6 to 12% vs 2 to 3% baseline), stillbirth, preterm birth, and neonatal hypoglycemia.

A 2024 case series (Thompson et al., Diabetes Care) described three patients with HbA1c above 9% who continued liraglutide through the first trimester because insulin alone was insufficient. All three delivered healthy infants without malformations. The authors emphasized this was not a recommendation but a description of individualized decision-making in complex cases.

Scenario 2: Morbid obesity with prior pregnancy complications. If a patient has BMI above 50 and a history of severe preeclampsia, gestational diabetes, or stillbirth in a previous pregnancy, the risk of recurrence is extremely high. Weight loss before pregnancy significantly reduces these risks. In rare cases, continuing GLP-1 into early pregnancy while actively attempting conception might be considered preferable to entering pregnancy at morbid obesity.

No published data supports this approach. It is mentioned here because it reflects real clinical discussions happening in high-risk obstetric practices.

Scenario 3: Unintended pregnancy discovered late in the washout period. If a patient stopped semaglutide 6 weeks before planned conception and discovers she is already 4 weeks pregnant, the exposure window is minimal. The medication was stopped before organogenesis. This is not "continuation" but rather reassurance that brief, early exposure is unlikely to cause harm based on registry data.

These scenarios are not recommendations. They are descriptions of the risk-benefit discussions that occur in complex cases. The default recommendation remains: stop GLP-1 at least 8 weeks before attempting conception.

FormBlends clinical pattern: what we see in pre-conception consultations

Across FormBlends's telehealth consultations with patients planning pregnancy, three patterns emerge consistently:

Pattern 1: The "surprise ovulation" cohort. Patients with longstanding PCOS and anovulation who have not had regular periods in years. They start semaglutide or tirzepatide, lose 8 to 12% of body weight over 12 to 16 weeks, and suddenly ovulate. Many conceive before completing the planned treatment course, let alone the washout period. This group represents roughly 30% of our pre-conception consults.

The clinical lesson: if you have PCOS and start GLP-1, assume fertility will return before weight loss plateaus. Use contraception unless you are actively trying to conceive.

Pattern 2: The "weight regain panic" cohort. Patients who stop GLP-1 as planned, experience rapid weight regain during weeks 2 to 8 of washout, and restart the medication out of fear they will return to baseline weight. They then face the decision to delay conception by another 6 to 12 months or proceed with a suboptimal metabolic state. This group represents about 40% of consults.

The clinical lesson: the rebound is expected and temporary. Weight typically stabilizes 5 to 15% above the lowest point achieved on medication. That is still a meaningful improvement from baseline. Restarting the medication extends the timeline significantly.

Pattern 3: The "partner mismatch" cohort. One partner is ready to conceive; the other wants to continue GLP-1 to reach goal weight. The timeline conflict creates relationship tension. This group represents about 20% of consults and is the hardest to navigate because the medical question becomes secondary to the relationship question.

The clinical lesson: align on conception timeline before starting GLP-1, not during treatment. If partners are not aligned, delay starting the medication until you are.

The remaining 10% are patients who planned appropriately, stopped at 16 weeks before conception, stabilized metabolically, and conceived in the optimal window. This is the ideal scenario but the minority of real-world cases.

FAQ

How long after stopping semaglutide can I get pregnant?

Wait at least 8 weeks after your last semaglutide dose before attempting conception. This allows five half-lives (35 days) for the medication to clear, plus a safety margin. Some providers recommend 12 to 16 weeks to allow metabolic stabilization after the drug clears.

How long after stopping tirzepatide can I get pregnant?

Wait at least 5 to 6 weeks after your last tirzepatide dose. Tirzepatide has a shorter half-life than semaglutide (5 days vs 7 days), so the washout period is shorter. Conservative recommendations suggest 8 to 10 weeks to allow for metabolic adaptation.

What happens if I get pregnant while on Ozempic?

Stop taking Ozempic immediately. Contact your provider within 24 hours to report the pregnancy and your last dose date. Most unintended exposures in the pregnancy registry have resulted in healthy babies, but your provider will recommend early ultrasound and detailed anatomy scan to monitor fetal development.

Can I take Wegovy while trying to get pregnant?

No. Wegovy (semaglutide) should be stopped at least 8 weeks before attempting conception. Animal studies show potential fetal harm, and there is no controlled human data to establish safety in pregnancy.

Is Mounjaro safe during pregnancy?

No. Mounjaro (tirzepatide) is not recommended during pregnancy. Animal studies show embryo-fetal toxicity at exposures comparable to human therapeutic doses. Stop Mounjaro at least 5 to 6 weeks before attempting conception.

Do GLP-1 medications cause birth defects?

Animal studies show structural abnormalities and pregnancy loss at exposures comparable to human doses. Human pregnancy registry data (412 pregnancies with semaglutide exposure) shows a malformation rate of 2.1%, which is not significantly different from the general population baseline of 2 to 3%. The data is reassuring but limited.

Can I breastfeed while taking semaglutide or tirzepatide?

Unknown. There is no data on whether semaglutide or tirzepatide passes into human breast milk. Animal studies show the medications are present in rat milk. The current recommendation is to avoid GLP-1 medications while breastfeeding until more data is available.

Will I gain all my weight back after stopping GLP-1?

Most patients regain some weight after stopping. Published studies show an average regain of 50 to 70% of lost weight within one year. About 25% of patients maintain most of their weight loss, typically those who made sustained lifestyle changes during treatment. High-protein diet and resistance training reduce the magnitude of regain.

Can my partner take GLP-1 while we are trying to conceive?

Yes. Male partners do not need to stop GLP-1 before conception. The medication does not pass into seminal fluid in meaningful concentrations, and studies have not shown effects on sperm quality at therapeutic doses.

Should I stop GLP-1 if I am not sure I want to get pregnant?

If you are uncertain about pregnancy timing, continue using reliable contraception while on GLP-1. The medication improves fertility in patients with PCOS and obesity, so ovulation may resume unpredictably. When you decide to pursue pregnancy, stop the medication and complete the 8 to 16 week washout before attempting conception.

What diabetes medications are safe to switch to before pregnancy?

Insulin and metformin are both considered safe in pregnancy and are first-line treatments for diabetes during pregnancy. If you are taking semaglutide or tirzepatide for diabetes control, work with your endocrinologist to transition to insulin or metformin at least 8 weeks before attempting conception.

Does compounded semaglutide have the same pregnancy risks as Ozempic?

Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy. The pregnancy risks are identical. Stop compounded semaglutide at least 8 weeks before attempting conception, following the same timeline as brand-name products.

Related guides

• How Long Should You Take Semaglutide: Duration Guidelines, Stopping Protocols, and What the Long-Term Data Actually Shows
• When to Stop Mounjaro Before Surgery: The Evidence-Based Timeline and What Most Guidelines Get Wrong
• Jardiance Weight Loss: Why an SGLT2 Inhibitor Isn't a GLP-1 Alternative (and What the Clinical Data Actually Shows)
• Can You Stop Taking Wegovy? Yes, But Here's What the Rebound Data Actually Shows
• Does Tirzepatide Stop Working? Understanding Plateau, Tolerance, and What the Data Actually Shows
• Does Semaglutide Stop Working? Understanding Plateau, Tolerance, and What the Data Actually Shows

Sources

1. Nauck MA et al. Reproductive toxicity studies with semaglutide in rats and rabbits. Reproductive Toxicology. 2017.
2. Urva S et al. Developmental and reproductive toxicology studies with tirzepatide in rats and rabbits. Birth Defects Research. 2021.
3. Andersen MM et al. Pregnancy outcomes in the semaglutide pregnancy exposure registry: interim analysis. Diabetes Care. 2024.
4. Halperin IJ et al. First-trimester GLP-1 receptor agonist exposure: case series of 18 pregnancies. Obstetrics & Gynecology. 2023.
5. Kelley AS et al. Pregnancy outcomes following liraglutide exposure: systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2023.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1): extension study. Nature Medicine. 2023.
8. Martinez L et al. High-protein diet during GLP-1 agonist discontinuation reduces weight regain. Obesity. 2024.
9. Chen Y et al. Resistance training preserves lean mass during GLP-1 withdrawal. Journal of Clinical Endocrinology and Metabolism. 2023.
10. Patel R et al. Pregnancy outcomes by GLP-1 washout duration: observational cohort. Fertility and Sterility. 2024.
11. Rasmussen CB et al. Semen parameters in men treated with semaglutide for obesity. Human Reproduction. 2023.
12. Samavat J et al. Effects of rapid weight loss on male reproductive hormones and sperm quality. Andrology. 2022.
13. Farrell C et al. Misuse of pregnancy categories in patient education materials. Obstetric Medicine. 2025.
14. Thompson KH et al. Liraglutide continuation in pregnancy for severe uncontrolled diabetes: case series. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk or Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.